Latest Solu Therapeutics News & Updates

See the latest news and media coverage for Solu. We track all announcements, press releases, and industry mentions in real time, all in one place.

Solu Therapeutics (Solu)

Clinical-stage therapeutic platform biotechnology company

solutherapeutics.com

Headquarters: Boston , United States
Company type: Private company
Number of employees: 10–22
Industry: Pharmaceuticals

Last updated November 4

Latest news about Solu Therapeutics (Solu)

In short: Solu initiated STX-0712 dosing in its AML cohort and received FDA Fast Track designation for CMML.

Company announcements

June 22 Solu

Solu Therapeutics received FDA Fast Track designation.

The designation is for their lead CyTAC program targeting relapsed or refractory CMML.

May 27 Solu

Solu Therapeutics granted FDA Fast Track designation for STX-0712

The investigational therapy targets chronic myelomonocytic leukemia, an aggressive blood cancer with limited options.

April 9, 2024 Solu

Solu Therapeutics closes $41M Series A and doses first patient

The funding supports clinical evaluation of STX-0712, a novel CCR2-CyTAC therapy for CMML and other hematologic malignancies.

September 11, 2023 Solu

Solu Therapeutics appoints Philip Vickers as President and CEO

He succeeds co-founder David Donabedian and brings over 30 years of biopharma experience to lead development of CyTaC platform.

Media coverage

November 4 Yahoo Finance

Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer and immunology, today announced that initial results from its first-in-human Phase...

July 9 Business Wire

Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets

BOSTON--(BUSINESS WIRE)--Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced the closing of an oversubscribed $31 million...

April 9, 2025 CBS 6 News

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial...

June 22, 2023 Chemical & Engineering News

Solu launches for bifunctional small-molecule drugs

Solu Therapeutics has debuted with $31 million in seed financing to develop a small-molecule drug technology licensed from GSK. Called Cytotoxicity Targeting Chimera, or CyTaC...

Never miss news about Solu

Track Solu and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Solu competitors & trending companies

Browse news for competitors to Solu and other trending companies.